Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TET2 | Q6N021 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4845531 | 1.00 | TET2 (0.37) | TET2ALDH1A1TSHRMEN1CYP1A2 | |
| SCHEMBL4540907 | 0.81 | ALDH1A1 (0.44) | TET2ALDH1A1TSHRMEN1CYP1A2 | |
| SCHEMBL42929 | 0.79 | ALDH1A1 (0.38) | TET2ALDH1A1TSHRMEN1CYP1A2 | |
| SCHEMBL2505815 | 0.79 | ALDH1A1 (0.38) | TET2ALDH1A1TSHRMEN1CYP1A2 | |
| SCHEMBL938483 | 0.79 | ALDH1A1 (0.38) | TET2ALDH1A1TSHRMEN1CYP1A2 | |
| SCHEMBL9495447 | 0.78 | TET2 (0.40) | TET2ALDH1A1TSHRMEN1CYP1A2 | |
| SCHEMBL12159780 | 0.78 | TDP1 (0.38) | TDP1 | |
| SCHEMBL27686063 | 0.75 | ALDH1A1 (0.35) | ALDH1A1TSHRMEN1CYP1A2THRB | |
| SCHEMBL4226440 | 0.74 | TET2 (0.31) | TET2 | |
| SCHEMBL2562167 | 0.73 | LMNA (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7423152-B2 | Process for the manufacture of intermediates in camptothecin production | HOFFMAN-LA ROCHE INC. (US) | 2008-09-09 | — | — | US | disclosed |
| EP-1856124-A1 | NEW SYNTHESIS OF A CAMPTOTHECIN SUBUNIT | F. Hoffmann-Roche AG (CH) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006089657-A1 | NEW SYNTHESIS OF A CAMPTOTHECIN SUBUNIT | F. HOFFMAN-LA ROCHE AG (CH) | 2006-08-31 | — | — | WO | disclosed |
| US-20060189807-A1 | Process for the manufacture of intermediates in camptothecin production | F. HOFFMANN-LA ROCHE AG (CH) | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189807-A1 | Process for the manufacture of intermediates in camptothecin production | TOP1, TOP2A, AMPD1 | TET2 1350/4885ALDH1A1 327/4885TSHR 4090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.